Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Eisai (TSE:4523) has been drawing attention after mixed recent returns, including a 1 day decline and a loss over the past month, even though its total return over the past year remains positive.
See our latest analysis for Eisai.
Recent moves suggest momentum is mixed, with a 3.97% 7 day share price return offset by a 5.72% 30 day share price decline, while the 1 year total shareholder return of 2.94% contrasts with a weaker 3 and 5 year total shareholder record.
If Eisai’s uneven performance has you thinking about portfolio balance, this could be a good moment to scan 5 healthcare AI stocks and see which healthcare names stand out at present.
With Eisai trading at ¥4,482 and indicators like a 31% intrinsic discount alongside a modest 1 year return of 2.94%, you have to ask: is there real value here, or is the market already pricing in future growth?
With Eisai last closing at ¥4,482 against a widely followed fair value estimate of about ¥5,012, the current gap reflects a narrative built around Alzheimer’s treatments, long term cash flows and a specific discount rate of 4.8%.
The launch and approval of the home administered SC AI formulation for LEQEMBI, with high physician and patient anticipation, promises to unlock substantial incremental demand through enhanced convenience, improved treatment adherence, and reduced burden on healthcare systems, benefiting both topline revenues and margins through operational efficiencies and lower administration costs.
Want to see what kind of revenue ramp needs to sit behind that story? The narrative leans on steady top line growth, rising margins and a richer earnings profile. Curious how those moving parts stack up to justify today’s fair value and future profit multiple assumptions? The full narrative lays out the numbers behind that 10.6% gap.
Result: Fair Value of ¥5,012 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that 10.6% gap also leans heavily on LEQEMBI, so tougher drug pricing or any setback for the Alzheimer’s franchise could quickly challenge this storyline.
Find out about the key risks to this Eisai narrative.
The narrative calls Eisai undervalued by around 10.6%, yet its 25.6x P/E sits above peers at 19x, the JP pharmaceuticals average at 16.7x, and even its own 24.7x fair ratio. That gap suggests investors are already paying up. Is this really a discount, or just concentration risk around LEQEMBI priced in?
See what the numbers say about this price — find out in our valuation breakdown.
TSE:4523 P/E Ratio as at Feb 2026
If this story does not quite fit how you see Eisai, or you would rather crunch the numbers yourself, you can build a custom view in just a few minutes, Do it your way
A great starting point for your Eisai research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
If Eisai is only one piece of your watchlist, do not stop here. You could miss out on other ideas that better fit your goals and risk comfort.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 4523.T.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com